

# Formation sur la Qualité de Vie liée à la Santé dans les Essais Cliniques

*Educational Program on Health-Related Quality of Life (HRQL) in Clinical Trials*

*Mardi 8 avril 2003*

**ANAES - Kremlin-Bicêtre**

**Dr Olivier Chassany**

Coordonnateur Médical, Délégation Régionale A la Recherche Clinique,  
Hôpital Saint Louis, Paris

**Dr Catherine Acquadro**

Convenor du Groupe Qualité de Vie Cochrane, Lyon


# Evolution of HRQL assessment in clinical trials since 1966

## ☀ Literature search (Medline)

“Quality of Life” matched with “Clinical Trials”:

### Results: number of references

- ☀ 1966 to 1970: 0
- ☀ 1966 to 1980: 20
- ☀ 1966 to 1990: 210
- ☀ 1966 to 2000: 708



**Considerable increase of HRQL assessment in clinical trials**



# Cochrane Health-Related Quality of Life Methods Group

## Objective:

- To advise Cochrane reviewers about when and how to incorporate HRQL data into systematic reviews of health care interventions
- Convenors: Catherine Acquadro, MD  
Prof. Dick Joyce, PhD, FBPoS  
Prof. Donald L. Patrick, MSPH, PhD
- Coordinator: Lucile Lapalus (llapalus@mapi.fr)
- Active members : 37 from 12 countries

# Objectives

- **To help reviewers of clinical trials to acquire the skills needed to assess HRQL outcomes included in regulatory files and publications**
- **To facilitate decisions made by Health Authorities and health care providers**

# Presentation of the Workmats (1/2)

## ■ **Workmats :**

- ◆ large worksheets
- ◆ contain concise information: background
- ◆ present various assignments

## ■ **Workbook :**

- ◆ reference source
- ◆ additional information on HRQL



# Presentation of the Workmats (2/2)

- **Interactive learning method**
  
- **Participants**
  - ◆ **Small group discussions and interactions**
  - ◆ **To understand the new information**
  - ◆ **To complete the assignments through group discussions (writing material)**
  - ◆ **Group answers have to be discussed by all the groups to reach a consensus**

# Content

Workmats	Content
1	How do disease and treatment affect Health-Related Quality of Life (HRQL)?
2	Deciding which domains to include in a HRQL instrument
3	How is new HRQL questionnaire developed? 1 <sup>st</sup> step: Development of items and item reduction
4	Choosing an appropriate existing HRQL measure
5	Analysis of HRQL data
6	Presentation and interpretation of HRQL outcomes included in clinical trials?

# WORKMAT 1

**How do disease and treatment affect HRQL?**

# **WORKMAT 1 : (10h00 – 10h30)**

## ■ Learning objectives

- ◆ To identify the impact of health conditions and treatment on HRQL
- ◆ To distinguish the different ways diseases and treatment can affect HRQL
- ◆ To create an awareness that treatments can affect HRQL

# WORKMAT 1

## ■ Learning points

- ◆ Diseases and treatments can affect a person's quality of life in different ways
- ◆ HRQL is multidimensional and subjective

# WORKMAT 2

## Deciding which domains to include in HRQL instrument

# WORKMAT 2 : (10h45 – 11h15)

- **Learning objective**

- ◆ **To define the relevant HRQL domains depending on the conditions studied**

# WORKMAT 2

## ■ Learning points

- ◆ The relative burden of disease and treatment on population can be measured through HRQL domains
- ◆ At a minimum, HRQL consists of physical, psychological, and social domains
- ◆ The patient plays an important part in the development of a questionnaire

# WORKMAT 3

**How is a new HRQL questionnaire developed?**

**1<sup>st</sup> step: Development of items and item reduction**

# **WORKMAT 3 : (11h30 – 12h15)**

- **Learning objective**

- ◆ **To describe the process of HRQL instrument development**

# WORKMAT 3

## ■ Learning points

- ◆ Instrument development is a rigorous scientific process
- ◆ There is no single *right* way to develop an instrument although best practices are available for the steps in the process
- ◆ The instrument should have empirical evidence of validity

**Pause Repas: 12h30 – 14h00**

# Some definitions

- **Psychometrics:** Techniques by which we evaluate the quality of an instrument.
- **Test-retest Reliability (reproducibility):** Degree to which an instrument gives similar scores on repeated administrations in identical conditions to respondents who are assumed to be stable with respect to the domains being assessed. It is often based on the intra-class correlation coefficient (ordinal numbers); a reliability coefficient greater than 0.70 is considered as acceptable for group comparisons.
- **Responsiveness:** Ability of an instrument to detect small but important changes over time (delta change from baseline in a group of patients) or differences between treatment groups at a specified time. Responsiveness may be approached by capacity of the instrument to discriminate between clinically meaningful groups at a single time point (i.e., known groups validity), but this is not always proof that the instrument will be sensitive to HRQL change over time or to differences between treatment groups. Satisfactory effect size = 0.40 on most subscales (> 50%).
- **Validity:** Degree to which an instrument measures what it is intended to measure. Validating a health measure is the process of accumulating different kinds of evidence to determine the most appropriate interpretations of a health score. “Valid for what?”

# **WORKMAT 4**

## **Choosing an appropriate existing HRQL measure**

# **WORKMAT 4 : (14h00 – 14h45)**

## ■ **Learning objectives**

- ◆ **To explore the process for selecting an appropriate health status instrument for use in a specific clinical trial scenario**
- ◆ **To examine the trade-offs in the selection process**
- ◆ **To review the criteria necessary for appropriately evaluating an HRQL instrument**
- ◆ **To identify and evaluate established questionnaires for use in a specific patient group**

# WORKMAT 4

## ■ Learning points

- ◆ The first step is to ask yourself Key Questions
- ◆ The choice of domains and the selection of an HRQL instrument is influenced by severity and nature of the disease and the expected benefits and side effects of treatment

# **WORKMAT 5**

## **Analysis of HRQL data**

# **WORKMAT 5 : (15h00 – 15h45)**

## ■ Learning objectives

- ◆ To identify the issues and potential problems in designing a statistical analysis plan for HRQL data
- ◆ To understand the different methods of treating missing data
- ◆ To gain the knowledge and skills needed to analyze differences in HRQL outcomes between two or more treatments

# WORKMAT 5

## ■ Learning points

- ◆ To pre-specify hypotheses and to establish a rigorous analysis plan with a special focus on multiple test and missing data
- ◆ The type of missing data should be specified (missing items / missing questionnaires)

# **WORKMAT 6**

**Presentation and interpretation of HRQL  
outcomes included in clinical trials**

# **WORKMAT 6 : (16h00 – 16h45)**


## ■ **Learning objective**

- ◆ **To critically evaluate published literature describing HRQL surveys**
- ◆ **To interpret HRQL data that are reported in the published literature**

# WORKMAT 6

## ■ Learning points

- ◆ There are several ways to interpret; all have advantages and disadvantages : Effect Size (ES), Minimal Clinically Important Difference (MCID), Number of Patients to Treat (NNT)
- ◆ As the experience of interpreting HRQL outcomes is minor, raw HRQL scores may be difficult to interpret at the moment
- ◆ Attempts to interpret HRQL scores in different ways are recommended
- ◆ Though the evaluating techniques for HRQL data analysis are still in development, they are valuable nevertheless



# Conclusion & questions